ESMO 2023 | NeoTRIP: EFS in neoadjuvant atezolizumab with taxane/carboplatin ± anthracycline in high-risk TNBC

Kevin Kalinsky, MD, MS, from Emory University Hospital, Atlanta, GA, discussed the Phase III NeoTRIP (NCT002620280) study exploring the impact of adding atezolizumab to nab-paclitaxel/carboplatin in high-risk triple-negative breast cancer (TNBC). While the addition of atezolizumab showed a minor increase in pathologic complete response (pCR), the five-year event-free survival (EFS) did not significantly improve compared to the non-atezolizumab group (70.6% vs. 74.9%). Stratified analysis revealed no significant differences. Higher baseline stromal tumor-infiltrating lymphocytes (sTILs) were prognostic for better EFS, but PD-L1 expression and sTILs did not predict atezolizumab benefit. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.